Carregant...
The impact of reimbursement negotiations on cost and availability of new pharmaceuticals: evidence from an online experiment
BACKGROUND: The necessity to measure and reward “value for money” of new pharmaceuticals has become central in health policy debates, as much as the requirement to assess the “willingness to pay” for an additional, quality-adjusted life year (QALY). There is a clear need to understand the capacity o...
Guardat en:
| Publicat a: | Health Econ Rev |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer Berlin Heidelberg
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7243324/ https://ncbi.nlm.nih.gov/pubmed/32440753 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13561-020-00267-y |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|